Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cash & Current Investments: 2009-2024

Historic Cash & Current Investments for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $88.6 million.

  • Ironwood Pharmaceuticals' Cash & Current Investments rose 59.17% to $140.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $430.3 million, marking a year-over-year increase of 5.61%. This contributed to the annual value of $88.6 million for FY2024, which is 3.90% down from last year.
  • According to the latest figures from FY2024, Ironwood Pharmaceuticals' Cash & Current Investments is $88.6 million, which was down 3.90% from $92.2 million recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Cash & Current Investments registered a high of $657.5 million during FY2022, and its lowest value of $88.6 million during FY2024.
  • Moreover, its 3-year median value for Cash & Current Investments was $92.2 million (2023), whereas its average is $279.4 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first surged by 104.35% in 2020, then tumbled by 85.98% in 2023.
  • Yearly analysis of 5 years shows Ironwood Pharmaceuticals' Cash & Current Investments stood at $364.3 million in 2020, then surged by 70.58% to $621.4 million in 2021, then increased by 5.81% to $657.5 million in 2022, then plummeted by 85.98% to $92.2 million in 2023, then dropped by 3.90% to $88.6 million in 2024.